1415329-13-3

Basic information

• Product Name: VAL-CIT-PAB-MMAD
• Synonyms: VAL-CIT-PAB-MMAD;Vat-Cit-PAB-MMAD
• CAS NO: 1415329-13-3
• Molecular Formula: C₆₀H₉₃N₁₁O₁₁S
• Molecular Weight: 1176.51
• Mol File: 1415329-13-3.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: VAL-CIT-PAB-MMAD(CAS DataBase Reference)
• NIST Chemistry Reference: VAL-CIT-PAB-MMAD(1415329-13-3)
• EPA Substance Registry System: VAL-CIT-PAB-MMAD(1415329-13-3)

Safety Data

• Hazardous Substances Data: 1415329-13-3(Hazardous Substances Data)

Upstream product

• 1415329-11-1 4-((S)-2-((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-methylbutanamido)-5-ureidopentanamido)benzyl ((S)-1-(((S)-1-(((3R,4S,5S)-3-methoxy-1-((S)-2-((1R,2R)-1-methoxy-2-methyl-3-oxo-3-(((S)-2-phenyl-1-(thiazol-2-yl)ethyl)amino)propyl)pyrrolidin-1-yl)-5-methyl-1-oxoheptan-4-yl)(methyl)amino)-3-methyl-1-oxobutan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)(methyl)carbamate 
• 109-89-7 diethylamine 

Downstream Products

• 1415329-15-5 C₇₃H₁₀₄N₁₂O₁₆S 
• 1415329-16-6 C₇₀H₉₈N₁₂O₁₅S 
• 1415329-51-9 C₇₀H₁₁₁N₁₃O₁₄S 

Relevant articles and documents

Covalent Linkers in Antibody-Drug Conjugates and Methods of Making and Using the Same

The present invention provides novel and advantageous compositions having a linker capable of covalently coupling one or more free thiols of an antibody. Specifically, provided herein are the molecular structures, synthetic pathways, coupling mechanisms, and applications thereof as used in an antibody-drug conjugate (ADC).

PROSTATE-SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATES

This invention relates to prostate-specific membrane antigen (PSMA) antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are αPSMA antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the αPSMA antibodies of the invention are conjugated to one or more toxins. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, dolastatin analogs, and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology uses.